JONATHAN LEI to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications JONATHAN LEI has written about Xenograft Model Antitumor Assays.
Connection Strength
0.209
-
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors. Sci Transl Med. 2025 Aug 27; 17(813):eadq5492.
Score: 0.048
-
ZP4: A novel target for CAR-T cell therapy in triple negative breast cancer. Mol Ther. 2025 Apr 02; 33(4):1621-1641.
Score: 0.046
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
Score: 0.045
-
Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Res. 2021 12 15; 81(24):6259-6272.
Score: 0.037
-
Neurofibromin Is an Estrogen Receptor-a Transcriptional Co-repressor in Breast Cancer. Cancer Cell. 2020 03 16; 37(3):387-402.e7.
Score: 0.033